Literature DB >> 26064207

Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency.

Jiajia Xia1, Linman Li1, Wei Ren1, Xiaoya Zheng1, Chan Liu1, Jinchao Li1, Tingying Chen1, Xiaofeng Li1, Lingli Wang1, Yumei Hu1.   

Abstract

Adult growth hormone deficiency (AGHD) is correlated to many adverse effects on metabolism and increases cardiovascular risk. 40 patients with AGHD and 40 healthy subjects were included. Anthropometric parameters such as body mass index, waist circumference, and waist-hip ratio were measured. Meanwhile, plasma levels of total cholesterol, triglyceride, high sensitivity C-relative protein, interleukin-6 and OPG were determined. Homeostasis model assessments for insulin resistance (HOMA-IR) and β-cell function (HOMA-β) were calculated using homeostasis model. Plasma OPG concentrations of AGHD patients were significantly higher than those in healthy subjects (131.82 ± 45.04 versus 81.02 ± 45.04, P < 0.01). Plasma OPG levels were positively correlated with age, body mass index, waist circumference, hip circumference, waist-hip ratio, fasting insulin, total cholesterol, triglyceride, high sensitivity C-relative protein and interleukin-6 (P < 0.05), but negatively correlated with high-density lipoprotein cholesterol (P < 0.05). Multiple linear stepwise regression analysis demonstrated that body mass index, triglyceride, and interleukin-6 were independently related to plasma OPG levels (P < 0.05). The levels of plasma OPG were increased in AGHD patients and were closely correlated with glycolipid metabolism and chronic inflammation. OPG might play an important role in the occurrence and development of cardiovascular diseases in AGHD patients.

Entities:  

Keywords:  Adult growth hormone deficiency; cardiovascular disease risk; insulin tolerance test; osteoprotegerin

Year:  2015        PMID: 26064207      PMCID: PMC4443041     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  42 in total

1.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

2.  The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. .

Authors:  C Wüster; R Abs; B A Bengtsson; H Bennmarker; U Feldt-Rasmussen; E Hernberg-Ståhl; J P Monson; B Westberg; P Wilton
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

3.  Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study.

Authors:  D P Kiel; L I Kauppila; L A Cupples; M T Hannan; C J O'Donnell; P W Wilson
Journal:  Calcif Tissue Int       Date:  2001-05       Impact factor: 4.333

4.  Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Leonelo Bautista; Maria Grazia Franzosi; Patrick Commerford; Chim C Lang; Zvonko Rumboldt; Churchill L Onen; Liu Lisheng; Supachai Tanomsup; Paul Wangai; Fahad Razak; Arya M Sharma; Sonia S Anand
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

5.  Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis.

Authors:  Rasmus Mogelvang; Sune H Pedersen; Allan Flyvbjerg; Mette Bjerre; Allan Z Iversen; Soren Galatius; Jan Frystyk; Jan S Jensen
Journal:  Am J Cardiol       Date:  2011-11-17       Impact factor: 2.778

6.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-06       Impact factor: 5.958

Review 7.  Osteoblasts and bone formation.

Authors:  Joana Caetano-Lopes; Helena Canhão; João Eurico Fonseca
Journal:  Acta Reumatol Port       Date:  2007 Apr-Jun       Impact factor: 1.290

8.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

9.  The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study.

Authors:  Raphael See; Shuaib M Abdullah; Darren K McGuire; Amit Khera; Mahesh J Patel; Jason B Lindsey; Scott M Grundy; James A de Lemos
Journal:  J Am Coll Cardiol       Date:  2007-08-06       Impact factor: 24.094

10.  Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity.

Authors:  F L Hew; M Koschmann; M Christopher; C Rantzau; A Vaag; G Ward; H Beck-Nielsen; F Alford
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

View more
  2 in total

1.  Association between Visceral Fat and Bone Mineral Density in Both Male and Female Patients with Adult Growth Hormone Deficiency.

Authors:  Linman Li; Li Zhong; Xiaoya Zheng; Wenyi You; Yunting Wang; Jihui Yu; Xun Wu; Wei Ren; Gangyi Yang
Journal:  Biochem Res Int       Date:  2020-07-05

Review 2.  Role of circulating molecules in age-related cardiovascular and metabolic disorders.

Authors:  Yung Ting Hsiao; Ippei Shimizu; Yohko Yoshida; Tohru Minamino
Journal:  Inflamm Regen       Date:  2022-01-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.